Literature DB >> 1907753

Pathogenesis of Chagas' disease.

Z A Andrade1.   

Abstract

Entities:  

Mesh：

Year:  1991        PMID： 1907753     DOI： 10.1016/0923-2494(91)90021-a

Source DB:  PubMed          Journal:  Res Immunol        ISSN： 0923-2494


× No keyword cloud information.
  17 in total

1.  Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera.

Authors:  M C Thomas; M V Longobardo; E Carmelo; C Marañón; L Planelles; M E Patarroyo; C Alonso; M C López
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

2.  Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease.

Authors:  Christopher A Seid; Kathryn M Jones; Jeroen Pollet; Brian Keegan; Elissa Hudspeth; Molly Hammond; Junfei Wei; C Patrick McAtee; Leroy Versteeg; Amanda Gutierrez; Zhuyun Liu; Bin Zhan; Jonathan L Respress; Ulrich Strych; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-10-13       Impact factor: 3.452

3.  Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus.

Authors:  D Kaplan; I Ferrari; P L Bergami; E Mahler; G Levitus; P Chiale; J Hoebeke; M H Van Regenmortel; M J Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

4.  Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease.

Authors:  R L Tarleton; J Sun; L Zhang; M Postan
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease.

Authors:  F D Cordeiro; O A Martins-Filho; M O Da Costa Rocha; S J Adad; R Corrêa-Oliveira; A J Romanha
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

6.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease.

Authors:  Olindo Assis Martins-Filho; Silvana Maria Eloi-Santos; Andréa Teixeira Carvalho; Rodrigo Corrêa Oliveira; Anis Rassi; Alejandro Ostemayer Luquetti; Gustavo Gabriel Rassi; Zigman Brener
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

8.  Myocardial changes in acute Trypanosoma cruzi infection. Ultrastructural evidence of immune damage and the role of microangiopathy.

Authors:  Z A Andrade; S G Andrade; R Correa; M Sadigursky; V J Ferrans
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

9.  Mitochondrial complex III defects contribute to inefficient respiration and ATP synthesis in the myocardium of Trypanosoma cruzi-infected mice.

Authors:  Jian-Jun Wen; Nisha Jain Garg
Journal:  Antioxid Redox Signal       Date:  2010-01       Impact factor: 8.401

10.  Trypanosoma cruzi circulating in the southern region of the State of Mexico (Zumpahuacan) are pathogenic: a dog model.

Authors:  Alberto Barbabosa-Pliego; Hector M Díaz-Albiter; Laucel Ochoa-García; Esteban Aparicio-Burgos; Sandra M López-Heydeck; Valente Velásquez-Ordoñez; Raul C Fajardo-Muñoz; Sandra Díaz-González; Roberto Montes De Oca-Jimenez; Marco Barbosa-Mireles; Carmen Guzmán-Bracho; Jose G Estrada-Franco; Nisha Jain Garg; Juan C Vázquez-Chagoyán
Journal:  Am J Trop Med Hyg       Date:  2009-09       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.